New Pain Relief Study Using Spinal Cord Stimulation A Success, Says Medtronic
Based on data collated over three months, DTM spinal cord stimulation therapy (SCS) has been proved to aid in meaningful pain relief, according to medical device company Medtronic.
The multi-center study was prospective and on-label, showing significant relief while applying DTM SCS endurance therapy, which is a modified, reduced-energy variant of the Differential Target Multiplexed (DTM) Spinal Chord Simulation (SCS) therapy by Medtronic, which is generally used of chronic pain in the back, leg, or overall body.
A news release reported that, after 3 months, patients who had been treated with DTM SCS endurance therapy had found that their pain was relieved in a meaningful and noticable way. This was quantified as a reduction by 3.9cm in overall pain, using the 10cm Visual Analog Scale (VAS). Where back pain was concerned, an average of a 4.3cm decrease using the same scale was reported, and leg pain reports measured an average decrease of 5.0cm
The results after 3 months are consistent with collated from a previous feasibility study, according to Medtronic. Further data showed that, when measured using the Oswestry Disability Index, 69% of the patients involved had ascended to a less disabled category, 63% of whom reporting minimal to moderate disability at the 3 month mark, in comparison to only 16% at baseline. Furthermore, when asked how satisfied they were with the therapy after 3 months, 75% of the patients answered with “somewhat satisfied” or “very satisfied”.
Medtronic VP and GM of Pain Therapies within the Neuromodulation Business Charlie Covert said the following: “Every patient with chronic pain has their own unique needs, and Medtronic is committed to offering solutions that personalize care for our patients. For many, especially those who need or prefer a recharge-free SCS solution, our new DTM SCS endurance therapy offers meaningful clinical benefits by reducing pain, improving quality of life, and offering meaningful device longevity.”
On the basis of three-month data, DTM SCS endurance therapy can extend device longevity by 5.5 to 7.5 years when programmed using the Vanta recharge-free neurostimulator. When DTM SCS endurance therapy is programmed with the Intellis rechargeable neurostimulator, it allows for 2 options – rapid recharge, which takes around 5m per day, or a full charge of roughly 1hr every 12 days. A follow-up assessment will take place at six months and 12 months for patients enrolled in the study, Medtronic said. The three month findings of the study were recently presented at the 25th Annual Meeting of the North American Neuromodulation Society (NANS).